Tocilizumab offers clear benefit for hospitalised COVID-19 patients: RECOVERY

After months of conflicting results from smaller trials, the eagerly anticipated RECOVERY trial has found that the IL-6 inhibitor tocilizumab does in fact improve outcomes in patients hospitalised with COVID-19. “Previous trials of tocilizumab had shown mixed results, and it was unclear which patients might benefit from the treatment,” said Prof Peter Horby, of the ...

Already a member?

Login to keep reading.

© 2021 the limbic